This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look at lenacapavir as a capsid inhibitor for HIV
Ticker(s): GILDWho's the expert?
Institution: Boston University
- Associate Professor of Medicine and Microbiology
- treats about 20 patients per year for urogenital gonorrhea and is familiar the Phase 2 study of Gepotidacin for the treatment of uncomplicated urogenital gonorrhea
- Research interetst in human immunodeficiency virus type 1 (HIV-1) mucosal HIV-1 transmission and antibodies with a focus on the biological mechanisms for the selection observed during HIV-1 transmission
Interview Goaldiscussing the potential of Sunlenca (lencapavir) and the current landscape of HIV-1 treatments
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
